• Cryptocurrencies
  • Voorspellingsmarkten
  • Nieuws
  • Agentisch Handelen
  • Artikelen
  • Competities

Zoeken Cryptocurrencies

Trends Cryptocurrencies

CoinRithm

Bedrijf

Rechtspersoon
Bees-x Limited
Bedrijfsnummer
13308136
Opgericht in
England and Wales
Statutaire zetel
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm is een informatie- en onderzoeksdienst van Bees-x Limited. Het is niet door de Financial Conduct Authority (FCA) gemachtigd om gereguleerde activiteiten uit te voeren, en niets op deze site vormt financieel advies.

Ontdekken

CryptocurrenciesVoorspellingsmarktenNieuwsArtikelenAgent ArenaCompetities

Functies

DashboardNephandelAgentisch HandelenPortefeuilleVolglijstInstellingen

Bedrijf

Over OnsMethodologieGebruiks- voorwaardenPrivacybeleidCookiebeleidVrijwaring

Ondersteuning

KlantenserviceFAQOntwikkelaarskitMCP-documentatie

Sociale Media

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Rechten voorbehouden.
Verkrijgbaar via Google PlayDownloaden in de App Store
  • Home
  • MarktenVoorspellingsmarkten
  • Nieuws
  • Dashboard
  1. Voorspellingsmarkten
  2. Health & Medicine
  3. When will the FDA reclassify BPC-157 to Category 1?
When will the FDA reclassify BPC-157 to Category 1?

When will the FDA reclassify BPC-157 to Category 1?

4.0% (24u)Health & MedicineOne-Off19d
KalshiKalshiBeschikbaarheid controlerenKYC vereist2% kosten
Huidige impliciete kans
Before July
Before July 5%+4.0%
Koploper van 6 uitkomsten
Marktkwaliteit

28 / 100

Lage kwaliteit
24u volume

€ 0,1

Liquiditeit

€ 103,8

Lage liquiditeit
Bied / Laat

1.0% / 6.0%

Spread

500.0%

Brede spread
Marktdata

Bijgewerkt 2 minuten geleden

24 mrt 26, 14:001 jul 26, 3:59

Trends

Uitkomst24uKans

Gekozen uitkomst

Before July5%

Regels

If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Apr 15, 2026, then the market resolves to Yes.

Kalshi
  • The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility.
  • Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before May 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jul 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.

Gerelateerde Markten

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

€ 145,3K
Ja: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

€ 16,6K
Ja: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

€ 8,7K
Ja: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

€ 1,3K
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

€ 462,5
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

€ 137,8
2025: 0%Manifold MarketsMANIFOLD MARKETS

Actief in deze onderwerpen

BitcoinBTC$62,871.62+2.52%EthereumETH$1,658.53+1.90%SolanaSOL$65.29+1.89%DogecoinDOGE$0.085+1.76%XRPXRP$1.12+0.73%BNBBNB$596.99+1.87%

Gerelateerd Nieuws

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Regels

If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Apr 15, 2026, then the market resolves to Yes.

Kalshi
  • The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility.
  • Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before May 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jul 1, 2026, then the market resolves to Yes.
  • If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.